Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate the association between them, and the potential clinical implicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Makris, Anastasios, Barkas, Fotios, Sfikakis, Petros P., Liberopoulos, Evangelos, Filippatos, Theodosios D., Ray, Kausik K., Agouridis, Aris P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500445/
https://www.ncbi.nlm.nih.gov/pubmed/37720252
http://dx.doi.org/10.1016/j.athplu.2023.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500445/
https://www.ncbi.nlm.nih.gov/pubmed/37720252
http://dx.doi.org/10.1016/j.athplu.2023.09.001

Ejemplares similares